Channel Wealth LLC Acquires 11,847 Shares of Boston Scientific Corporation $BSX

Channel Wealth LLC increased its stake in Boston Scientific Corporation (NYSE:BSX) by 70.8% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 28,577 shares of the medical equipment provider’s stock after purchasing an additional 11,847 shares during the period. Channel Wealth LLC’s holdings in Boston Scientific were worth $2,790,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of the stock. Steph & Co. purchased a new position in Boston Scientific in the 3rd quarter worth approximately $25,000. 1248 Management LLC bought a new stake in shares of Boston Scientific during the 1st quarter worth $26,000. FWL Investment Management LLC bought a new stake in shares of Boston Scientific during the 2nd quarter worth $26,000. Sound Income Strategies LLC grew its position in Boston Scientific by 90.9% in the second quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider’s stock worth $27,000 after acquiring an additional 120 shares in the last quarter. Finally, Kilter Group LLC purchased a new position in Boston Scientific in the second quarter worth $30,000. 89.07% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

BSX has been the topic of a number of research reports. Robert W. Baird raised their price target on Boston Scientific from $123.00 to $128.00 and gave the company an “outperform” rating in a research report on Wednesday, October 1st. Oppenheimer raised Boston Scientific from a “market perform” rating to an “outperform” rating and raised their price objective for the company from $118.00 to $125.00 in a report on Monday, September 8th. Erste Group Bank lowered Boston Scientific from a “buy” rating to a “hold” rating in a research note on Friday, October 3rd. UBS Group reissued a “buy” rating on shares of Boston Scientific in a research note on Wednesday. Finally, Morgan Stanley boosted their price objective on shares of Boston Scientific from $125.00 to $130.00 and gave the stock an “overweight” rating in a report on Thursday, October 23rd. Two investment analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $125.35.

Insider Transactions at Boston Scientific

In related news, Director Ellen M. Zane sold 12,891 shares of the business’s stock in a transaction dated Thursday, November 6th. The stock was sold at an average price of $98.28, for a total transaction of $1,266,927.48. Following the transaction, the director owned 24,134 shares in the company, valued at $2,371,889.52. The trade was a 34.82% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of the company’s stock in a transaction that occurred on Monday, November 3rd. The shares were sold at an average price of $99.47, for a total value of $4,973,500.00. Following the transaction, the executive vice president directly owned 178,342 shares of the company’s stock, valued at $17,739,678.74. The trade was a 21.90% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 143,095 shares of company stock worth $14,228,950. Company insiders own 0.50% of the company’s stock.

Boston Scientific Stock Up 1.7%

Shares of Boston Scientific stock opened at $94.53 on Thursday. The company has a debt-to-equity ratio of 0.47, a quick ratio of 0.96 and a current ratio of 1.51. Boston Scientific Corporation has a 52-week low of $85.98 and a 52-week high of $109.50. The company’s 50 day moving average price is $98.66 and its 200-day moving average price is $101.37. The stock has a market capitalization of $140.14 billion, a price-to-earnings ratio of 50.55, a P/E/G ratio of 1.87 and a beta of 0.67.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 earnings per share for the quarter, beating the consensus estimate of $0.71 by $0.04. The business had revenue of $5.07 billion during the quarter, compared to analysts’ expectations of $4.97 billion. Boston Scientific had a net margin of 14.43% and a return on equity of 19.46%. The firm’s revenue for the quarter was up 20.3% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.63 EPS. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS and its Q4 2025 guidance at 0.770-0.790 EPS. Equities research analysts forecast that Boston Scientific Corporation will post 2.85 EPS for the current year.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.